{"id":778886,"date":"2025-12-10T10:29:01","date_gmt":"2025-12-10T10:29:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=778886"},"modified":"2025-12-10T10:29:01","modified_gmt":"2025-12-10T10:29:01","slug":"in-vitro-diagnostics-market-rising-to-usd-15763-billion-by-2030-amid-personalized-medicine-and-technological-innovation","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/in-vitro-diagnostics-market-rising-to-usd-15763-billion-by-2030-amid-personalized-medicine-and-technological-innovation_778886.html","title":{"rendered":"In Vitro Diagnostics Market: Rising to USD 157.63 Billion by 2030 Amid Personalized Medicine and Technological Innovation"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1765366621.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"In Vitro Diagnostics Market: Rising to USD 157.63 Billion by 2030 Amid Personalized Medicine and Technological Innovation\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1765366621.jpg\" alt=\"In Vitro Diagnostics Market: Rising to USD 157.63 Billion by 2030 Amid Personalized Medicine and Technological Innovation\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>In Vitro Diagnostics Market by Product &#038; Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) &#038; Region- Global Forecast to 2030<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Some of the prominent players operating in the market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US)<\/div>\n<p style=\"text-align: justify;\">The <strong>global In Vitro Diagnostics (IVD) Market<\/strong>, valued at <strong>US$100,769.3 million in 2024<\/strong>, is poised for strong expansion, reaching <strong>US$109,065.5 million in 2025<\/strong> and an impressive <strong>US$157,632.5 million by 2030<\/strong> at a <strong>7.6% CAGR<\/strong>. As healthcare systems worldwide transition toward precision medicine, early detection, and decentralized testing, IVD solutions continue to play a central role in modern clinical decision-making.<\/p>\n<p style=\"text-align: justify;\">This rapid ascent is driven by the growing burden of chronic diseases, major advances in molecular diagnostics, adoption of point-of-care testing, and increased investment in diagnostic infrastructure&mdash;particularly across emerging markets. Simultaneously, the aging population in regions such as North America, Europe, and Japan is fueling continuous demand for clinical testing, supporting strong market growth through the forecast period.<\/p>\n<p style=\"text-align: justify;\"><strong>Download PDF Brochure: <a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=703&amp;utm_source=abnewswire.com&amp;utm_medium=paidpr&amp;utm_campaign=invitrodiagnosticsmarket\"  target=\"_blank\">https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=703<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Market Drivers Shaping the Global IVD Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Rising Prevalence of Chronic and Infectious Diseases<\/strong><\/p>\n<p style=\"text-align: justify;\">Chronic illnesses such as <strong>diabetes, cardiovascular diseases, cancer, and autoimmune disorders<\/strong> are rapidly increasing worldwide. This surge requires <strong>more frequent, accurate, and targeted diagnostic testing<\/strong>, placing IVD technologies at the center of patient monitoring and therapy selection.<\/p>\n<p style=\"text-align: justify;\">Additionally, periodic outbreaks of infectious diseases&mdash;including COVID-19, influenza, and emerging viral infections&mdash;continue to reinforce the need for scalable diagnostic systems.<\/p>\n<p style=\"text-align: justify;\"><strong>2. Acceleration in Advanced Diagnostic Technologies<\/strong><\/p>\n<p style=\"text-align: justify;\">Several high-impact technology domains are transforming the IVD industry:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Molecular diagnostics<\/strong> enabling genetic-level testing<\/p>\n<\/li>\n<li>\n<p><strong>Next-generation sequencing (NGS)<\/strong> improving speed and accuracy of genomic insights<\/p>\n<\/li>\n<li>\n<p><strong>Liquid biopsy<\/strong> providing non-invasive cancer detection<\/p>\n<\/li>\n<li>\n<p><strong>Digital and AI-enhanced diagnostics<\/strong> enabling real-time analysis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Together, these innovations support personalized medicine, enabling rapid diagnosis, companion diagnostics for targeted therapies, and broader access to precision healthcare.<\/p>\n<p style=\"text-align: justify;\"><strong>3. Expanding Adoption of Point-of-Care (POC) and At-Home Testing<\/strong><\/p>\n<p style=\"text-align: justify;\">The demand for <strong>portable, rapid, and user-friendly diagnostic devices<\/strong> continues to surge due to:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Increased outpatient and home-based care<\/p>\n<\/li>\n<li>\n<p>Need for faster diagnosis in emergency and critical-care settings<\/p>\n<\/li>\n<li>\n<p>Rising consumer emphasis on self-monitoring<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">POC diagnostics are particularly valuable in underserved and rural areas with limited access to high-complexity laboratory infrastructure.<\/p>\n<p style=\"text-align: justify;\"><strong>4. Growing Global Geriatric Population<\/strong><\/p>\n<p style=\"text-align: justify;\">Aging populations in highly developed regions experience significantly higher rates of chronic conditions and infections, necessitating continuous diagnostic monitoring.<\/p>\n<p style=\"text-align: justify;\">The demographic shift in <strong>Europe, Japan, and the United States<\/strong> drives sustained test utilization, supporting long-term IVD market expansion.<\/p>\n<p style=\"text-align: justify;\"><strong>5. Government Support and Infrastructure Investments in Emerging Markets<\/strong><\/p>\n<p style=\"text-align: justify;\">Countries across <strong>Asia Pacific, Latin America, Africa, and the Middle East<\/strong> are scaling diagnostic infrastructure through:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>National screening programs<\/p>\n<\/li>\n<li>\n<p>Digital health initiatives<\/p>\n<\/li>\n<li>\n<p>Investments in lab modernization<\/p>\n<\/li>\n<li>\n<p>Strengthened regulatory frameworks<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">These investments are expanding access to high-quality diagnostics, boosting market penetration for global and regional IVD players.<\/p>\n<p style=\"text-align: justify;\"><strong>Market Segmentation Insights<\/strong> <strong>By Product: Reagents &amp; Kits Lead the Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The IVD market is segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Reagents &amp; kits<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Instruments<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Data management software and services<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">In <strong>2024<\/strong>, the <strong>reagents &amp; kits segment<\/strong> held the highest growth rate. The strong performance is driven by:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>High-volume usage in recurring diagnostic processes<\/p>\n<\/li>\n<li>\n<p>Advances in assay sensitivity and specificity<\/p>\n<\/li>\n<li>\n<p>Innovations supporting automation and workflow efficiency<\/p>\n<\/li>\n<li>\n<p>Increasing demand for personalized and companion diagnostics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Regulatory enhancements ensuring stringent quality standards also contribute to greater confidence and adoption among clinical laboratories and clinicians.<\/p>\n<p style=\"text-align: justify;\"><strong>By Specimen Type: Blood, Serum, and Plasma Remain Dominant<\/strong><\/p>\n<p style=\"text-align: justify;\">The market is segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Blood, serum, and plasma specimens<\/p>\n<\/li>\n<li>\n<p>Saliva specimens<\/p>\n<\/li>\n<li>\n<p>Urine specimens<\/p>\n<\/li>\n<li>\n<p>Other specimen types<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">In <strong>2024<\/strong>, <strong>blood, serum, and plasma<\/strong> accounted for the largest market share. Their dominance stems from:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Wide clinical utility across routine and specialized tests<\/p>\n<\/li>\n<li>\n<p>High compatibility with immunoassays, molecular tests, and genetic profiling<\/p>\n<\/li>\n<li>\n<p>Established workflows in hospital and central laboratories<\/p>\n<\/li>\n<li>\n<p>Consistent reliability in detecting biomarkers for acute and chronic conditions<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Given their accuracy and compatibility with advanced platforms, blood-based samples will maintain their strong adoption throughout the forecast period.<\/p>\n<p style=\"text-align: justify;\"><strong>By Geography: North America Leads the Global IVD Market<\/strong><\/p>\n<p style=\"text-align: justify;\">North America remains the largest regional market due to a combination of technological leadership, strong healthcare spending, and robust adoption of advanced diagnostic modalities.<\/p>\n<p style=\"text-align: justify;\">Key contributing factors include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>High uptake of <strong>lab-on-a-chip systems<\/strong>, <strong>digital diagnostics<\/strong>, and <strong>high-throughput analyzers<\/strong><\/p>\n<\/li>\n<li>\n<p>Growth in precision medicine programs focused on genomic, proteomic, and metabolomic testing<\/p>\n<\/li>\n<li>\n<p>Significant healthcare expenditure growth: The <strong>US Centers for Medicare &amp; Medicaid Services<\/strong> projects <strong>NHE growth (5.6%) to outpace GDP growth (4.3%)<\/strong> from 2023&ndash;2032, increasing healthcare&rsquo;s share of GDP from <strong>17.3% to 19.7%<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Major players such as <strong>Abbott, Thermo Fisher Scientific, BD, and Danaher<\/strong> continue to lead innovation through advanced research pipelines, strong distribution networks, and strategic partnerships with hospitals and universities.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Players in the Global IVD Market<\/strong><\/p>\n<p style=\"text-align: justify;\">Prominent companies operating across the IVD value chain include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Danaher (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>F. Hoffmann-La Roche Ltd (Switzerland)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Abbott (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Siemens Healthineers AG (Germany)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Thermo Fisher Scientific Inc. (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Illumina, Inc. (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Hologic, Inc. (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Bio-Rad Laboratories, Inc. (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>bioM&eacute;rieux (France)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Sysmex Corporation (Japan)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Revvity (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>BD (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Agilent Technologies (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Qiagen (Netherlands)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>DiaSorin S.p.A. (Italy)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Grifols S.A. (Spain)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Werfen (Spain)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>QuidelOrtho Corporation (US)<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">These industry leaders are accelerating innovation through acquisitions, product launches, regulatory approvals, and investment in AI-enabled diagnostics.<\/p>\n<p style=\"text-align: justify;\"><strong>Conclusion<\/strong><\/p>\n<p style=\"text-align: justify;\">The global <strong>In Vitro Diagnostics market<\/strong> is undergoing a transformative period marked by rapid technological innovation, growing need for early disease detection, and expanding access across emerging economies. With strong demand for molecular diagnostics, NGS platforms, high-throughput systems, and point-of-care solutions, the market is set to reach <strong>US$157.63 billion by 2030<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Pages : <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=703&amp;utm_source=abnewswire.com&amp;utm_medium=paidpr&amp;utm_campaign=invitrodiagnosticsmarket\"  target=\"_blank\">https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=703<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_145966.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Rohan Salgarkar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=in-vitro-diagnostics-market-rising-to-usd-15763-billion-by-2030-amid-personalized-medicine-and-technological-innovation\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>1615 South Congress Ave.  Suite 103, Delray Beach, FL 33445<br \/><strong>City:<\/strong> Florida<br \/><strong>State:<\/strong> Florida<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/ivd-in-vitro-diagnostics-market-703.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/ivd-in-vitro-diagnostics-market-703.html<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=in-vitro-diagnostics-market-rising-to-usd-15763-billion-by-2030-amid-personalized-medicine-and-technological-innovation\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In Vitro Diagnostics Market by Product &#038; Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) &#038; Region- Global Forecast to 2030 Some of the prominent players operating in the market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/in-vitro-diagnostics-market-rising-to-usd-15763-billion-by-2030-amid-personalized-medicine-and-technological-innovation_778886.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-778886","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/778886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=778886"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/778886\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=778886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=778886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=778886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}